Can Mono Cause Liver Enzymes to Be High?

Mono raises liver enzymes in the vast majority of people who get sick with it. Roughly nine out of ten patients with infectious mononucleosis show at least mildly elevated liver enzymes during the course of their illness, even when they have no obvious liver-related symptoms like yellowing skin or abdominal pain.¹ The liver involvement is so routine that doctors sometimes use liver enzyme results to help confirm a mono diagnosis. Yet most people never realize their liver was affected at all, because the elevation is usually modest and resolves on its own.

How Often Mono Affects the Liver

Infectious mononucleosis is caused primarily by the Epstein-Barr virus (EBV), and its classic symptoms are the ones everyone hears about: extreme fatigue, sore throat, swollen lymph nodes, and fever. What gets far less attention is how consistently the liver is involved. A systematic review looking across multiple studies found that about 62% of mono patients had elevated ALT (a key liver enzyme), 57% had elevated AST (another liver enzyme), and 65% had elevated alkaline phosphatase.² Those percentages reflect the proportion of patients who crossed the clinical threshold for “abnormal.” When researchers use more sensitive cutoffs, the proportion climbs even higher, toward that 90% figure.

People with mono also frequently develop physical enlargement of the liver and spleen. In the same systematic review, clinical hepatomegaly (a liver you can feel on examination because it is larger than normal) showed up in about 35% of patients, and splenomegaly (an enlarged spleen) appeared in 44%.² On ultrasound, spleen enlargement was found in every patient examined. So even when a blood test catches only a modest enzyme bump, the liver and its neighboring organs are often under stress.

Which Enzymes Go Up and by How Much

The liver enzymes that spike during mono are the same ones your doctor checks in a standard metabolic panel or liver function test: ALT, AST, and GGT. In a study comparing mono patients to matched controls, all three were significantly higher in the mono group.³ The increase is typically described as “mild to moderate,” meaning your numbers might be two to five times the upper limit of normal. That sounds alarming if you are staring at a lab printout, but it is a far cry from the dramatic surges seen in true viral hepatitis (hepatitis A, B, or C), where enzymes can climb to ten or twenty times normal.

An older but frequently cited study found that AST was abnormal in about 97% of EBV mono cases, making it the single most consistently abnormal liver marker in the disease.⁴ Bilirubin, by contrast, stays normal for most patients. Jaundice (visible yellowing of the skin and eyes from high bilirubin) occurs in fewer than about one in six mono patients, and is sometimes considered a red flag that something more complicated is going on.²

Occasionally the pattern of liver injury looks “mixed,” meaning it shows features of both hepatocellular damage (injury to liver cells themselves) and cholestatic injury (disruption of bile flow). One case report documented this mixed pattern and noted it can create confusion in diagnosis, since pure cholestatic patterns point toward different causes like gallstones or drug reactions.⁵

Why the Liver Gets Involved

The mechanism behind mono’s liver effects is not what most people would expect. EBV does not typically infect liver cells directly. Instead, it infects B cells (a type of immune cell), and the immune system launches a massive counter-attack using CD8+ T cells. Those activated T cells flood into the liver, causing inflammation and spotty death of liver tissue as collateral damage. Research examining liver biopsies from patients with severe EBV hepatitis has confirmed that the virus was present in the T cells infiltrating the liver, not in the liver cells themselves.⁶ A separate study looking at liver tissue from patients with unexplained liver disease found EBV genetic material in the tissue, with CD8+ T cells identified as the dominant infiltrating cells.⁷

This means the liver enzyme elevation is largely a byproduct of your immune system doing its job. The stronger the immune response, the more inflammation in the liver, and the higher the enzymes. It also helps explain why the elevation is usually self-limiting: once the immune system gets the virus under control, the inflammatory siege on the liver winds down.

Age Makes a Significant Difference

One of the clearest patterns in the research is that older patients tend to have worse liver involvement from mono. In young children, EBV infection is often asymptomatic or causes only mild illness. As age increases, so does the likelihood and severity of liver enzyme elevation.

A study of hospitalized children found that elevated liver enzymes occurred in about 27% of kids under five, 63% of children aged five to nine, and 77% of those ten and older.⁸ Another study comparing youth and preschool-age children confirmed that the incidence of liver injury was significantly higher in the older group.⁹

The gap becomes even more dramatic when comparing children to adults. A study directly comparing the two groups found that nearly all adults with mono (99%) had some degree of liver injury, compared with about 68% of children. Adults also had substantially higher enzyme levels: median ALT of 368 versus 90 in children, and median AST of 227 versus 68.¹⁰ Adults also had longer fevers, longer hospital stays, and higher rates of splenomegaly. One source estimates that the incidence of liver dysfunction runs about 10% in younger patients and as high as 30% in older patients when using stricter clinical definitions.¹¹

The practical takeaway is that if you are a teenager or young adult getting mono for the first time, expect your liver enzymes to be at least somewhat elevated. If you are in your thirties or older and contract primary EBV, your liver is almost certainly going to show the strain.

When Mono Looks Like Hepatitis

Because elevated liver enzymes are the hallmark of hepatitis, mono can initially look identical to viral hepatitis A, B, or C on a blood panel. This creates a real diagnostic puzzle, especially in cases where a patient has jaundice and elevated enzymes but does not present with the classic sore throat and swollen lymph nodes of mono. One study found that only 12% of patients with confirmed EBV hepatitis actually showed the full textbook triad of fever, sore throat, and lymphadenopathy, though all of them had elevated lymphocyte counts on their blood work.¹²

A 2025 case report described a patient whose acute EBV hepatitis was confirmed only after hepatitis A, B, C, and E had all been ruled out through blood testing.¹³ One potentially useful clue is spleen size: researchers have found that measuring the spleen by ultrasound can help tell mono apart from hepatitis, since the spleen tends to enlarge considerably in mono but not in garden-variety viral hepatitis.¹⁴

If you get blood work showing elevated liver enzymes and your doctor starts testing you for hepatitis, it is worth mentioning any recent mono-like symptoms, even mild ones. EBV should be on the differential diagnosis for any unexplained acute hepatitis, especially in younger adults.

CMV Mono and the Liver

EBV is the most common cause of mono, but cytomegalovirus (CMV) can cause an almost identical syndrome. CMV mono also affects the liver, though perhaps slightly less consistently. The same older study that found AST elevation in 97% of EBV mono patients found it in about 88% of CMV mono cases.⁴ Both types cause mild to moderate enzyme elevation rather than the extreme spikes of hepatitis A or B. A more recent study of CMV hepatitis found elevated liver tests in about 69% of patients with acute CMV infection, with 9% developing jaundice.¹⁵

Clinically, the distinction matters less than you might think, since both types are usually self-limiting. But if your mono test (the rapid heterophile antibody test, or “Monospot”) comes back negative and your liver enzymes are still elevated, CMV is one of the leading alternate explanations your doctor should consider.

Rare but Serious Liver Complications

For the overwhelming majority of people, the liver enzyme elevation from mono resolves completely without any specific treatment. The liver heals itself. But in rare cases, EBV can trigger severe or even fatal liver failure, and those cases are worth knowing about.

The U.S. Acute Liver Failure Study Group reviewed nearly 1,900 adult patients enrolled over 14 years and found four cases (about 0.2%) where EBV was the cause of acute liver failure. Two of those patients died, one required a liver transplant, and one survived with supportive care.¹⁶ A separate case report documented fulminant EBV infection leading to liver failure, splenic rupture, and esophageal damage requiring multiple surgeries.¹⁷

People with underlying immune deficiencies are at especially elevated risk. A report described a patient with X-linked lymphoproliferative disease (a rare inherited immune disorder) who developed fulminant hepatitis and multi-organ failure from EBV, ultimately dying despite intensive care.¹⁸ Another serious complication is hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system goes into overdrive and starts destroying the body’s own blood cells. EBV can trigger HLH, and when it does, the liver often takes severe damage. One case described a 23-year-old who developed HLH and acute liver injury six weeks after an initial mono diagnosis.¹⁹ In the most severe HLH cases, liver failure can be fatal even with intensive treatment including plasma exchange and organ support.²⁰

These outcomes are genuinely rare. But if you have mono and develop worsening jaundice, persistent high fevers that are not improving after a week or two, unexplained bruising, or severe abdominal pain, those are signals to seek urgent medical attention rather than waiting it out.

Practical Considerations While Your Liver Recovers

Because the liver enzyme elevation is almost always mild and self-limiting, no specific liver treatment is needed for typical mono. But there are a few things worth keeping in mind during recovery.

Acetaminophen (Tylenol) is commonly used for fever and pain during mono, and it is generally considered appropriate. However, doctors recommend using it cautiously and at the lowest effective dose, since the liver is already under some strain from the infection.¹ Alcohol is another obvious thing to avoid while your liver enzymes are elevated, though most people with active mono feel too miserable to drink anyway.

The spleen enlargement that accompanies mono is the reason doctors tell patients to avoid contact sports and vigorous physical activity during the illness. A ruptured spleen is the most feared acute complication of mono, and it is more likely when the spleen is swollen. The standard guidance is to avoid strenuous activity for at least three weeks after symptom onset, though some athletes and their doctors extend the restriction until imaging confirms the spleen has returned to normal size.

If your doctor orders follow-up bloodwork a few weeks after your mono diagnosis, do not be alarmed if your liver enzymes are still above normal. They typically take a few weeks to normalize, and in some cases it can stretch to a couple of months. Persistent elevation beyond that, or enzymes that initially improve and then spike again, warrants further investigation to rule out other causes.

Risk Factors for Worse Liver Involvement

Not everyone’s liver reacts equally to mono. Research on children has identified a few factors that predict more significant liver injury: older age, female sex, and the presence of splenomegaly all independently raised the odds.²¹ Male patients, interestingly, show a different pattern in some analyses. One study found that men with the highest enzyme quartile had much stronger statistical associations with a mono diagnosis than women with similarly high enzymes, suggesting that while men may be less likely overall to develop liver symptoms, when they do, the enzyme elevation tends to be more pronounced.³

The evidence on sex differences is not entirely consistent across studies, which is not unusual in infectious disease research where populations, diagnostic thresholds, and study designs vary. What is consistent is the age effect: older patients get hit harder.

A Possible Long-Term Link to Fatty Liver Disease

Most discussions of mono and the liver focus on the acute phase. But an intriguing population-level study has raised the possibility that mono leaves a longer footprint on liver health. Researchers found that within ten years of a mono diagnosis, about 2.6% of patients had developed non-alcoholic fatty liver disease (NAFLD), compared with 1.8% of matched individuals who never had mono. After adjusting for other risk factors, the hazard ratio was about 1.73, meaning mono patients were roughly 73% more likely to develop fatty liver disease over the following decade.²²

This is a single observational study, so the connection could reflect shared risk factors rather than a direct causal link. EBV is known to persist in the body for life after primary infection, lingering in B cells in a dormant state, so a biological mechanism is at least plausible. But it is too early to say that having mono means you should worry about fatty liver disease later. The finding is more a signal for researchers to investigate further than a reason for patients to change their behavior. What it does reinforce is that EBV’s relationship with the liver is more complex and potentially more lasting than the textbook “mild transient hepatitis” framing suggests.

1
PubMed Central. Return to Play After Infectious Mononucleosis
2
PubMed. The utility of liver function tests and abdominal ultrasound in infectious mononucleosis-A systematic review
3
PubMed Central. Infectious mononucleosis and hepatic function
4
Clinical Chemistry. Hepatic function in mononucleosis induced by Epstein-Barr virus and cytomegalovirus
5
PubMed Central. Hepatocellular-Cholestatic Pattern of Liver Injury in a Patient With Infectious Mononucleosis
6
Human Pathology. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes
7
PubMed. The role of Epstein-Barr virus in acute and chronic hepatitis
8
Korean Journal of Pediatrics. Clinical features of Epstein-Barr virus-associated infectious mononucleosis in hospitalized Korean children
9
PubMed Central. Clinical characteristics of infectious mononucleosis in preschool children and youth patients
10
PubMed Central. The Difference in Clinical Features and Hepatic Injury Characteristics Between Children and Adults With Infectious Mononucleosis
11
PubMed Central. Recurrence of infectious mononucleosis in adults after remission for 3 years: A case report – Section: DISCUSSION
12
PubMed. Characteristics of Epstein-Barr virus hepatitis among patients with jaundice or acute hepatitis
13
Clinical Medicine. Acute Epstein–Barr virus hepatitis without infectious mononucleosis: a diagnostic challenge
14
PubMed. Differentiation of mononucleosis from hepatitis by sonographic measurement of spleen size
15
PubMed. Hepatitis due to Epstein-Barr virus and cytomegalovirus: clinical features and outcomes
16
PubMed Central. Epstein–Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group
17
PubMed Central. Fulminant Epstein-Barr virus – infectious mononucleosis in an adult with liver failure, splenic rupture, and spontaneous esophageal bleeding with ensuing esophageal necrosis: a case report
18
PubMed Central. Fulminant liver failure due to Epstein-Barr virus in immunodeficiency disorders
19
PubMed Central. Acute liver injury secondary to hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection
20
PubMed. A case of hemophagocytic lymphohistiocytosis after the primary Epstein-Barr virus infection
21
PubMed Central. Clinical Characteristics and the Risk Factors of Hepatic Injury in 221 Children With Infectious Mononucleosis
22
PubMed. Infectious mononucleosis is associated with an increased incidence of NAFLD